Rockefeller Capital Management L.P. Acquires 25,169 Shares of BridgeBio Pharma, Inc. $BBIO

Rockefeller Capital Management L.P. increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 189.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 38,429 shares of the company’s stock after buying an additional 25,169 shares during the period. Rockefeller Capital Management L.P.’s holdings in BridgeBio Pharma were worth $2,939,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp bought a new stake in BridgeBio Pharma in the first quarter worth about $35,000. First Trust Advisors LP boosted its holdings in BridgeBio Pharma by 200.4% in the 2nd quarter. First Trust Advisors LP now owns 263,693 shares of the company’s stock worth $11,386,000 after buying an additional 175,918 shares during the period. Baird Financial Group Inc. boosted its holdings in BridgeBio Pharma by 1.8% in the 2nd quarter. Baird Financial Group Inc. now owns 42,057 shares of the company’s stock worth $1,816,000 after buying an additional 731 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in BridgeBio Pharma in the 2nd quarter valued at approximately $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in BridgeBio Pharma by 2.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company’s stock valued at $4,132,000 after buying an additional 2,206 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Price Performance

NASDAQ BBIO opened at $70.24 on Monday. The company’s 50 day simple moving average is $68.88 and its two-hundred day simple moving average is $71.81. BridgeBio Pharma, Inc. has a 1 year low of $41.80 and a 1 year high of $84.94. The stock has a market capitalization of $13.76 billion, a PE ratio of -18.78 and a beta of 0.98.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The firm had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. BridgeBio Pharma’s quarterly revenue was up 66.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.88) EPS. On average, research analysts anticipate that BridgeBio Pharma, Inc. will post -2.29 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on BBIO. Citigroup started coverage on BridgeBio Pharma in a research report on Tuesday, May 19th. They set a “neutral” rating and a $82.00 target price on the stock. Mizuho reduced their price target on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a research report on Tuesday, June 16th. Weiss Ratings reiterated a “sell (d)” rating on shares of BridgeBio Pharma in a research note on Friday, May 15th. William Blair began coverage on BridgeBio Pharma in a report on Tuesday, March 10th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity Group began coverage on BridgeBio Pharma in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 target price for the company. Twenty-one analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average target price of $92.90.

Insider Activity at BridgeBio Pharma

In related news, CFO Thomas Trimarchi sold 13,651 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $65.08, for a total transaction of $888,407.08. Following the completion of the transaction, the chief financial officer directly owned 359,194 shares in the company, valued at $23,376,345.52. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer E. Cook sold 37,167 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $2,601,690.00. Following the completion of the transaction, the director owned 8,383 shares in the company, valued at $586,810. This represents a 81.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 306,361 shares of company stock valued at $21,020,442 in the last ninety days. 14.23% of the stock is currently owned by corporate insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.